In Reply In discussing the topic of injection drug use–associated infective endocarditis in our review,1 our intent was to highlight the lack of certainty with respect to the use of surgery and outcomes in these patients. Cardiac surgery in patients with injection drug use–associated infective endocarditis has been associated with higher mortality and reoperation in the first 6 months after surgery than in patients with infective endocarditis not related to injection drug use.2 Surgical decision-making about infective endocarditis is complicated in general. For example, approximately 1 in 4 patients with infective endocarditis (regardless of whether they use intravenous drugs) with indications for surgery do not receive surgery as part of their management, particularly those with infective endocarditis due to Staphylococcus aureus.3 An important and challenging aspect of managing infective endocarditis is addressing host factors that impede the use of surgery when indications are present. With injection drug use–associated infective endocarditis, the risks of ongoing addiction, injection drug use, and infection relapse or recurrence adds greater complexity that needs to be addressed. We agree that addiction treatment is a crucial aspect of care for patients with injection drug use–associated infective endocarditis and is often suboptimally addressed.4 Also, we regret if readers perceived any unintended negativity or judgment with respect to the terminology used in our brief discussion of injection drug use–associated infective endocarditis.
Wang A, Gaca JG, Chu VH. Injection Drug Use-Associated Infective Endocarditis—Reply. JAMA. 2018;320(18):1939–1940. doi:10.1001/jama.2018.14075
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: